The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
Launched by STANFORD UNIVERSITY · May 29, 2018
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called Tranexamic Acid (TXA) on joint inflammation and cartilage health in patients who have recently torn their anterior cruciate ligament (ACL). The goal is to see if TXA can help reduce inflammation and improve joint health after an ACL injury and surgery, potentially preventing or delaying the development of arthritis over time.
To participate in this study, individuals need to be between 18 and 30 years old and must have experienced a recent ACL injury (within the last four days) with some swelling or bleeding in the knee. Unfortunately, those with certain pre-existing joint conditions, previous knee surgeries, or other specific health issues may not be eligible. Participants will receive TXA treatment shortly after their injury and surgery, and the study will monitor their joint health over time. This trial is currently recruiting, and anyone interested should reach out for more information to see if they qualify.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 18-30 years
- • within 4 days of unilateral ACL injury
- • presence of effusion/hemarthrosis.
- Exclusion Criteria:
- • inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
- • systemic or acute illness requiring medications
- • concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
- • prior surgery to either knee
- • prior injury to either knee requiring crutches
- • history of thromboembolic disease
- • current use of combination hormonal contraception
- • chronic NSAID use
- • cortisone injection to either knee within the prior 3 months
- • not indicated for or unable to undergo ACLR within 3 months of injury
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Constance Chu, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials